It’s only fair to share… Icovamenib CAS 2448172-22-1 MF C31H34N8O3 MW 566.7 g/mol N-{4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-4-{[(3R)-3-(prop-2-enamido) piperidin-1-yl]methyl}pyridine-2-carboxamide N-[4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-4-[[(3R)-3-(prop-2-enoylamino)piperidin-1-yl]methyl]pyridine-2-carboxamidemenin-MLL (mixed-lineage leukemia) protein interaction inhibitor,antineoplastic, BMF-219, BMF 219, 2Z737MY35A, Menin-MLL inhibitor 21 Icovamenib is an investigational irreversible covalent inhibitor of menin. It is developed by Biomea Fusion for diabetes, lymphoma, leukemia, and multiple myeloma.[1][2][3]Icovamenib is an orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic …